Target intelligence / Profile preview

Ribosome biogenesis protein C1orf109 (AIRIM)

Target
AIRIM
Molecular classification
Other (Ribosome biogenesis factor)
01

Overview

Ribosome biogenesis protein C1orf109 (AIRIM) is a cytoplasmic and nuclear protein involved in the cytoplasmic maturation steps of pre-60S ribosomal particles, specifically by promoting the release of shuttling factors required for ribosome assembly[9][4][1]. It acts together with other factors like SPATA5, SPATA5L1, and CINP to coordinate late steps of large ribosomal subunit biogenesis[2]. Loss of C1orf109 impairs 60S ribosomal subunit maturation, disrupts global protein synthesis, and is associated with the appearance of abnormal polysomes indicative of ribosome assembly defects[2][4]. C1orf109 is not a classical pharmacological target (e.g., receptor, enzyme), nor are there known drugs or direct disease associations outside of ribosome biogenesis defects[2][9]. It is evolutionarily conserved and may interact with other proteins involved in DNA replication and ribosome maturation[2]. It is located in the cytosol, nucleus, and nucleolus[9]. The gene is also known as FLJ20508 and AFG2-interacting ribosome maturation factor, among others.

Other names
AFG2 interacting ribosome maturation factorAIRIMC1orf109Ribosome biogenesis protein C1orf109FLJ20508AFG2-interacting ribosome maturation factorUncharacterized protein C1orf109
02

Biological functions

Ribosome large subunit biogenesisCytoplasmic maturation of pre-60S ribosomal particlesProtein synthesis regulationCell proliferation (linked but not its primary classification)
03

Disease associations

Other (Ribosomopathies; potential link to neurodevelopmental disorders and cancer via cell proliferation regulation)

Beyond the preview

Go deeper on Ribosome biogenesis protein C1orf109 (AIRIM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosome biogenesis protein C1orf109 (AIRIM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call